4D Advisors LLC Purchases Shares of 75,000 DexCom, Inc. (NASDAQ:DXCM)

4D Advisors LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 75,000 shares of the medical device company's stock, valued at approximately $5,833,000. DexCom makes up approximately 4.1% of 4D Advisors LLC's investment portfolio, making the stock its 6th biggest holding.

Several other large investors also recently added to or reduced their stakes in the business. Acorn Financial Advisory Services Inc. ADV boosted its position in DexCom by 42.8% during the 4th quarter. Acorn Financial Advisory Services Inc. ADV now owns 20,565 shares of the medical device company's stock valued at $1,599,000 after buying an additional 6,166 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in shares of DexCom by 110.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,345 shares of the medical device company's stock valued at $1,582,000 after purchasing an additional 10,666 shares in the last quarter. LGT Financial Advisors LLC purchased a new stake in DexCom during the 4th quarter valued at about $93,000. Freestone Grove Partners LP purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $7,778,000. Finally, Voleon Capital Management LP bought a new stake in shares of DexCom in the 4th quarter worth $4,505,000. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 over the last quarter. 0.32% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DXCM shares. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday. Barclays lifted their price target on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a report on Monday. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Mizuho initiated coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $98.11.

DexCom Trading Down 1.7 %

Shares of NASDAQ:DXCM traded down $1.35 on Monday, hitting $80.27. 5,371,321 shares of the company's stock were exchanged, compared to its average volume of 4,270,825. The stock has a market capitalization of $31.47 billion, a price-to-earnings ratio of 56.13, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $132.26. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business's 50 day simple moving average is $71.46 and its two-hundred day simple moving average is $76.87.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 EPS. Analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.